



CLOSED-LOOP ARTIFICIAL INTELLIGENCE PLATFORM FOR LIPID NANOPARTICLE OPTIMIZATION USING MICROFLUIDIC PROCESSING, BAYESIAN OPTIMIZATION, AND STABILITY FEEDBACK

Claire Martin¹, Julien Robert^{2*}, Sophie Bernard¹, Antoine Girard²

1. *Department of Pharmaceutical AI Systems, Faculty of Pharmacy, University of Lyon, Lyon, France.*
2. *Department of Computational Drug Research, Faculty of Medicine, University of Strasbourg, Strasbourg, France.*

ARTICLE INFO

Received:

09 November 2024

Received in revised form:

15 January 2025

Accepted:

17 January 2025

Available online:

28 February 2025

Keywords: Lipid nanoparticles, mRNA delivery, Bayesian optimization, Autonomous formulation, Microfluidics, Closed-loop AI

ABSTRACT

Lipid nanoparticles are the leading nonviral platform for mRNA delivery, but their formulation requires coordinated optimization of lipid composition, microfluidic mixing conditions, RNA encapsulation, particle quality, and storage stability. This creates a high-dimensional development problem that is difficult to solve through static experimentation alone. Traditional formulation development often depends on sequential design-of-experiments workflows that do not adaptively learn from each new batch. As a result, stability behavior, manufacturability, and delivery performance may be evaluated too late in development, when reformulation becomes costly. This manuscript proposes a closed-loop artificial intelligence platform that links automated microfluidic LNP preparation with Bayesian optimization. The platform would iteratively select the next formulation experiment based on predicted size, polydispersity, encapsulation efficiency, and stability behavior. The conceptual platform includes a microfluidic synthesis robot, integrated particle characterization modules, stability measurement workflows, a Gaussian process surrogate model, an acquisition function optimizer, and a supervisory controller. Together, these components would allow autonomous experiment selection, execution, measurement, and model updating. Such a platform could improve formulation efficiency by learning from each experimental cycle and navigating trade-offs among competing critical quality attributes. It would also create a reusable knowledge base linking formulation variables, process fingerprints, product quality, and stability outcomes. Closed-loop AI could transform RNA nanomedicine formulation from a largely manual screening process into an adaptive, data-driven development system. This framework provides a conceptual foundation for autonomous LNP optimization without claiming experimental validation or numerical performance outcomes.

This is an **open-access** article distributed under the terms of the [Creative Commons Attribution-Non Commercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, and build upon the work non commercially.

To Cite This Article: Martin C, Robert J, Bernard S, Girard A. Closed-Loop Artificial Intelligence Platform for Lipid Nanoparticle Optimization Using Microfluidic Processing, Bayesian Optimization, and Stability Feedback. *Pharmacophore*. 2025;16(1):11-20. <https://doi.org/10.51847/aszACuik9e>

Introduction

The clinical success of mRNA vaccines has made lipid nanoparticles central to modern RNA nanomedicine, but the formulation of these systems remains complex because structure, composition, manufacturing conditions, and storage behavior jointly determine product quality. Studies of mRNA-LNP vaccine structure and stability have shown that lipid organization, RNA protection, and physicochemical integrity are tightly coupled, making formulation development more than a simple excipient-selection task [1]. Machine learning studies have begun to address this complexity by predicting LNP performance for mRNA vaccines [2] and by using model-guided optimization to improve vaccine quality attributes [3]. However, most current workflows still rely on human-directed iteration rather than a fully integrated closed-loop system.

The LNP design space includes ionizable lipid identity, helper lipid selection, cholesterol proportion, PEG-lipid content, aqueous-to-organic mixing ratio, total flow rate, RNA concentration, and downstream storage conditions. Microfluidic technologies provide controlled mixing environments for RNA-loaded LNP production [4], while scalable and parallelized systems show how manufacturing parameters can be systematically varied across many formulations [5, 6]. Yet mixing method alone can alter mRNA delivery efficacy and organ tropism [7], meaning that process variables cannot be separated from

Corresponding Author: Julien Robert; Department of Computational Drug Research, Faculty of Medicine, University of Strasbourg, Strasbourg, France. E-mail: julien.robert@gmail.com.

biological and quality outcomes. This motivates an adaptive platform in which formulation and process variables are optimized together rather than treated as independent development stages.

Closed-loop AI platforms are increasingly influential in materials and formulation science because they combine experimental automation with algorithmic decision-making. Bayesian optimization has already been applied to pharmaceutical product development as a strategy for efficiently exploring formulation spaces [8], while machine-learning-assisted approaches have accelerated biopharmaceutical formulation design and vaccine formulation development. Self-driving laboratory concepts have also demonstrated how automated experimentation can advance Pareto fronts for material properties. These developments suggest that autonomous nanomedicine formulation is technically plausible, even though closed-loop LNP optimization remains less mature than supervised LNP prediction.

This article proposes a conceptual AI systems framework in which a Bayesian optimizer selects the next LNP formulation, a microfluidic module fabricates the batch, characterization modules measure critical quality attributes, and stability feedback updates the surrogate model. Recent LNP-specific AI studies provide important foundations, including deep learning platforms for mRNA delivery development [9], AI-driven ionizable lipid design [10], and AI-guided LNP design for pulmonary gene therapy [11]. The proposed framework differs from these prior efforts by emphasizing an integrated closed-loop architecture rather than a single predictive model. It is therefore positioned as an autonomous formulation platform that could support iterative, multi-objective LNP development without claiming experimental results.

Figure 1 presents the proposed closed-loop AI architecture linking LNP formulation design, microfluidic synthesis, process fingerprinting, CQA and stability measurement, Bayesian decision-making, biosecurity guardrails, and human-supervised formulation selection.




Figure 1. AI-Driven LNP mRNA Formulation and Manufacturing Workflow

Background

Lipid Nanoparticle Composition and Microfluidic Processing

LNPs typically combine an ionizable lipid, a helper phospholipid, cholesterol, and a PEG-lipid to balance RNA encapsulation, colloidal stability, endosomal release, and manufacturability. Foundational work on ionizable lipid-containing nanoparticles showed that particle formation and morphology depend on lipid composition and assembly conditions [12], while studies of siRNA and mRNA co-delivery demonstrated how formulation choices influence nucleic acid loading and delivery behavior [13]. Phospholipid chemistry can further modulate mRNA delivery, showing that helper lipid selection is not a passive background variable [14]. Microfluidic production adds another layer of control because flow rate ratio, total flow rate, and chip geometry influence mixing kinetics, particle size, and encapsulation behavior [4, 15].

Quality Attributes and Stability of LNP-RNA Formulations

Critical quality attributes for LNP-RNA systems include particle size, polydispersity, encapsulation efficiency, RNA integrity, lipid composition, and stability under storage or stress conditions. Analytical characterization methods for liposomes and lipid nanoparticles provide the measurement foundation needed to assess these attributes [16]. Stability studies of mRNA-LNP vaccines emphasize that colloidal stability and RNA protection must be evaluated together rather than as isolated endpoints [1]. Lyophilization studies further show that long-term stability can be improved through formulation and process choices [17, 18], supporting the need to integrate stability feedback early in autonomous optimization.

Bayesian Optimization and Gaussian Process Surrogates

Bayesian optimization is suitable for formulation problems because it can search expensive, noisy, and high-dimensional experimental spaces using a probabilistic surrogate model. Pharmaceutical applications of Bayesian optimization show how surrogate-guided learning can reduce inefficient screening by selecting experiments that balance expected performance and uncertainty [8]. In vaccine and biologics formulation development, Bayesian and machine-learning approaches have been used

to guide multi-objective decisions where stability, manufacturability, and product quality must be considered simultaneously. In the proposed platform, Gaussian process modeling would provide both prediction and uncertainty, allowing the system to decide whether to exploit promising LNP conditions or explore poorly characterized regions.

Self-Driving Laboratories and Autonomous Experimentation

Self-driving laboratories combine robotic experimentation, automated data capture, machine learning, and decision algorithms into an iterative cycle that proposes and tests new experimental conditions. The self-driving laboratory model has advanced materials discovery by autonomously navigating trade-offs among properties and improving Pareto-front exploration. For LNP development, comparable autonomy would require integration of microfluidic fabrication, particle characterization, stability workflows, and AI-based experiment selection. Scalable microfluidic systems for mRNA and siRNA LNP production [5] and throughput-oriented manufacturing approaches for mRNA vaccines [6] provide important hardware precedents for such a platform.

Prior AI Approaches to Nanoparticle Design

Prior AI studies in LNP development have mainly focused on supervised prediction, rational lipid design, or model-assisted screening rather than full closed-loop experimentation. Machine learning has been used to predict LNP performance for mRNA vaccines [2], understand manufacturing-process effects [19], and optimize mRNA-LNP vaccine quality through XGBoost, Bayesian methods, and ensemble approaches [3]. More recent systems use deep learning to accelerate LNP development [9], design ionizable lipids for mRNA delivery [10], and guide pulmonary gene therapy nanoparticle formulation [11]. Reviews of machine learning for LNP formulation and process development emphasize the growing promise of these methods while also highlighting the need for more integrated, adaptive, and experimentally connected workflows [20–22].

Platform Architecture Overview

High-Level Closed-Loop Workflow

The proposed platform begins when the Bayesian optimizer proposes a candidate LNP formulation defined by lipid composition, RNA loading conditions, microfluidic settings, and storage-relevant factors. The microfluidic station then fabricates the LNP under programmable mixing conditions, reflecting evidence that chip design and mixing method can influence particle properties and delivery outcomes [7, 23, 24]. In-line or at-line characterization generates particle size, polydispersity, encapsulation, and early stability measurements, which are returned to the AI engine for model updating. This closed loop would allow the platform to learn formulation–process–quality relationships continuously rather than treating each experiment as an isolated batch.

Core Hardware Modules

The hardware layer would include a programmable syringe-pump or pressure-driven microfluidic module, an LNP collection and dilution module, a dynamic light scattering unit, a fluorescence-based encapsulation assay module, and a controlled stability rack. Parallelized microfluidic production studies show how LNP synthesis can be scaled across multiple channels while maintaining controlled process execution [5], and later throughput-scalable manufacturing work demonstrates the relevance of automation to mRNA vaccine production workflows [6]. The characterization layer would draw on established lipid nanoparticle analytical principles for measuring size, heterogeneity, and formulation integrity [16]. The platform is conceptual, so these modules are described as an integrated architecture rather than as validated experimental equipment.

Design Principles

The system is designed around full-cycle automation, minimal human touchpoints, transparent constraint management, and compatibility with multiple RNA or nucleic acid payloads. It should remain payload-agnostic because LNP platforms may be adapted for mRNA, siRNA, and other nucleic acid delivery applications, as demonstrated by studies of co-delivery and lab-scale manufacturing across RNA payload types [13, 23]. It should also support compositional flexibility because advances in phospholipid chemistry and ionizable lipid design show that lipid structure can substantially affect delivery behavior [10, 14]. Finally, the platform should preserve formulation-scientist oversight by presenting Pareto-front options and uncertainty estimates rather than automatically declaring a single universal optimum.

Table 1 defines the functional architecture of the proposed closed-loop AI-LNP platform by linking each technical layer to its inputs, computational role, outputs, and conceptual contribution.

Table 1. Functional Architecture of the Closed-Loop AI-LNP Formulation Platform

Platform layer	Primary function	Key inputs	AI/system operation	Primary outputs	Scientific contribution to the manuscript
Formulation design-space layer	Defines the permissible LNP formulation search space	Lipid molar ratios, mRNA payload conditions, buffer constraints, process boundaries	Converts formulation knowledge into machine-readable variables and constraints	Candidate formulation vectors eligible for optimization	Establishes the platform as a constrained scientific optimizer rather than an unconstrained recipe generator

Microfluidic synthesis layer	Executes programmable LNP preparation	Aqueous RNA phase, organic lipid phase, flow-rate ratio, total flow rate, chip geometry	Translates AI-selected candidates into controlled physical batches	Prepared LNP samples with recorded manufacturing history	Links formulation optimization to reproducible process execution
Process-fingerprinting layer	Captures how each batch was produced	Flow traces, pressure signals, temperature logs, mixing history, device metadata	Converts manufacturing traces into structured process descriptors	Batch-specific process fingerprints	Allows the surrogate model to learn from manufacturing context, not formulation composition alone
Characterization layer	Measures immediate critical quality attributes	LNP samples, dilution metadata, DLS output, fluorescence assay output	Performs automated quality readout capture and validity checking	Size, PDI, encapsulation, assay-quality flags	Grounds AI learning in experimentally measurable LNP quality attributes
Stability-integration layer	Converts delayed stability behavior into optimization-ready features	Time-point samples, mRNA integrity, size drift, zeta-potential changes, storage condition records	Fits time-dependent stability descriptors and updates the model when delayed data arrive	Stability index, apparent degradation rates, delayed-response labels	Prevents optimization from favoring short-term particle quality at the expense of storage robustness
Bayesian decision layer	Selects the next experiment under uncertainty	Historical batch data, CQA values, stability labels, process fingerprints, constraints	Updates Gaussian process surrogate and optimizes acquisition function	Next candidate formulation or batch of candidates	Provides the central closed-loop intelligence of the platform
Pareto-navigation layer	Maintains multi-objective decision transparency	Predicted and observed CQA trade-offs	Ranks candidates across competing objectives without forcing a single universal optimum	Pareto archive and formulation trade-off map	Supports formulation-scientist judgment in selecting candidates based on risk-benefit priorities
Biosecurity governance layer	Prevents misuse and unsafe autonomous operation	Payload metadata, user permissions, request logs, institutional status, screening flags	Applies nucleic acid screening, access controls, misuse detection, refusal rules, audit logging, and red-team-tested constraints	Approved, blocked, quarantined, or escalated actions	Embeds responsible innovation directly into the technical platform architecture
Human-supervision layer	Ensures accountable deployment decisions	Pareto summaries, uncertainty reports, safety status, robustness evidence	Requires scientist review before continuation, scale-up, or knowledge-base transfer	Approved formulation candidates and documented decision rationale	Preserves expert oversight while allowing AI-assisted formulation acceleration

Microfluidic Data Acquisition and Process Fingerprinting

Real-Time Process Data Capture

A closed-loop LNP platform would record flow rate, pressure, temperature, solvent ratio, mixing sequence, and chip-use history during every formulation run. Studies of microfluidic RNA-LNP production show that device configuration and process parameters are central to particle formation [4, 15], while evaluations of different mixing techniques demonstrate that lab-scale manufacturing conditions can affect particle properties and efficiency [23]. The platform would convert these process traces into a “process fingerprint” that links how a particle was made to what quality attributes were observed. Such fingerprinting is necessary because the same nominal formulation may behave differently when prepared through different mixing methods or channel geometries [7, 24].

In-Line and At-Line Characterization for Size, PDI, and Encapsulation

Characterization modules would measure particle size, polydispersity, and encapsulation using automated sampling, dilution, and assay preparation routines. Analytical frameworks for lipid nanoparticles emphasize the need for orthogonal measurements because particle size, composition, and cargo integrity cannot be inferred from a single assay [16]. Machine-learning studies of LNP formulation further depend on reliable quality-attribute readouts to train models that connect input variables to formulation outcomes [2, 3, 19]. In the proposed platform, failed or implausible measurements would trigger repeat sampling or quarantine logic rather than being silently incorporated into the surrogate model.

Data Pre-Processing and Feature Extraction

Before model updating, raw process and characterization data would be cleaned, aligned, normalized, and transformed into features that the AI engine can interpret. Time-series process traces could be summarized through steady-state flow statistics, pressure fluctuation metrics, mixing onset features, and deviation scores, while particle data could be normalized to reduce instrument-to-instrument variability. Existing supervised learning frameworks for LNP performance prediction show the

importance of structured descriptors and curated input variables [2, 22], and manufacturing-focused machine learning studies highlight the value of process-aware features [19]. This feature layer would allow the optimizer to learn not only which formulations work, but also which manufacturing trajectories are associated with robust LNP quality.

AI Decision Engine – Bayesian Modeling and Acquisition

Gaussian Process Surrogate Modeling

The AI decision engine would train a multi-output Gaussian process surrogate on all prior batches, using formulation variables, microfluidic process fingerprints, and early stability indicators as inputs. For a candidate formulation (x), the model would estimate a posterior mean $\mu(x)$ and posterior variance $\sigma^2(x)$ for size, polydispersity, encapsulation, and a stability index, enabling predictions that include uncertainty rather than only point estimates. Bayesian optimization has already been proposed for pharmaceutical product development [8] and extended to vaccine and biologics formulation problems where uncertainty-aware decision-making is valuable. In the LNP context, this probabilistic surrogate would complement deep learning and supervised models that have been used to accelerate mRNA delivery development [9], predict nanoparticle performance [22], and guide lipid or formulation design [10, 11, 25].

Multi-Objective Acquisition Function

The acquisition function would translate surrogate predictions into the next experiment by balancing objectives such as higher encapsulation, lower polydispersity, acceptable particle size, and improved stability. For a single scalarized objective, the platform could use expected improvement, $EI(x) = (\mu(x) - f^*)\Phi(Z) + \sigma(x)\phi(Z)$, where $Z = \frac{\mu(x) - f^*}{\sigma(x)}$, (f^*) is the best observed value Φ and σ are the standard normal cumulative distribution and density functions. This formula operationalizes the trade-off between exploitation and exploration because high predicted performance increases $(\mu(x) - f^*)$, while uncertainty increases the $\sigma(x)\phi(Z)$ term. For true multi-objective LNP optimization, this logic could be extended to expected hypervolume improvement or Pareto-aware scalarization, consistent with broader self-driving laboratory strategies for advancing material-property trade-offs and formulation optimization studies using Bayesian or machine-learning approaches.

Figure 2 illustrates how the Bayesian decision engine converts formulation variables, process fingerprints, critical quality attributes, uncertainty estimates, and acquisition logic into the next supervised LNP experiment.




Figure 2. Bayesian Decision Engine for Multi-Objective LNP Formulation Optimization

Experiment Suggestion and Constraint Management

The optimizer would propose only physically and operationally feasible experiments by enforcing compositional constraints, chip operating limits, allowable solvent ratios, and predefined safety ranges for flow and pressure. These constraints are essential because LNP formation depends on lipid composition, morphology, and mixing behavior [12], while microfluidic production studies show that device design and operating conditions shape particle preparation outcomes [4–6, 24]. The platform could also recommend small batches of experiments when stability feedback is delayed, allowing active learning to continue while longer-term measurements mature. By combining formulation constraints with process constraints, the AI engine would function as a supervised decision layer rather than as an unconstrained generator of unrealistic experimental recipes.

Stability Data Integration and Multi-Objective Optimization

Stability Indicating Assays and Their Time-Series Nature

Stability feedback would be integrated as a time-dependent data stream rather than as a late-stage confirmation test, because mRNA-LNP quality depends on colloidal integrity, RNA protection, and storage behavior over time [1]. In the proposed platform, conceptual stability checkpoints at early and later intervals could track particle-size drift, mRNA integrity loss, and zeta-potential changes, with analytical interpretation grounded in established lipid nanoparticle characterization principles

[16]. A simple first-order stability model, $(C(t) = C_{0e}^{\{-kt\}})$, could be used to represent the decline of an integrity-related signal over time, where $(C(t))$ is the remaining signal at time (t) , (C_0) is the initial signal, and (k) is an apparent degradation or instability rate constant. Lyophilization and long-term mRNA-LNP stability studies show why such rate-derived descriptors should be incorporated early into formulation learning rather than evaluated only after candidate selection [17, 18].

Handling Delayed Stability Feedback in a Closed Loop

Because stability outcomes emerge more slowly than initial size, polydispersity, or encapsulation readouts, the platform would use batch-asynchronous Bayesian optimization to continue learning while delayed measurements mature. Bayesian optimization has been proposed for pharmaceutical product development because it can update decision rules as new evidence arrives without requiring exhaustive experimental grids [8]. In vaccine and biologics formulation contexts, machine-learning-guided optimization has been used conceptually to support multi-objective development decisions where stability and product quality evolve together. The closed-loop controller would therefore distinguish between immediate observations and pending stability labels, updating the surrogate when delayed outcomes become available rather than stalling all experimental planning. **Table 2** shows how batch-asynchronous Bayesian optimization integrates immediate formulation readouts with delayed stability endpoints to maintain continuous model updating and uninterrupted experimental decision-making despite time-lagged outcomes.

Table 2. Batch-asynchronous Bayesian optimization framework for stability-aware formulation development

Component	Role in platform	Timing of availability	Data type	Update behavior in Bayesian optimization loop
Initial physicochemical readouts (size, polydispersity, encapsulation efficiency)	Early surrogate signals of formulation quality	Immediate (post-experiment)	Continuous numerical	Used in initial surrogate model fitting and early acquisition decisions
Stability outcomes (e.g., aggregation, degradation, potency loss)	Primary long-term objective variables	Delayed (days–weeks)	Continuous / categorical	Incorporated asynchronously when matured; triggers posterior model update
Surrogate model	Predicts multi-objective formulation performance	Continuously active	Probabilistic predictions	Updated incrementally as new immediate and delayed data arrive
Acquisition function	Selects next experimental batch	Iterative (per batch cycle)	Utility score	Recomputed after each surrogate update, balancing exploration and exploitation
Batch execution module	Runs parallel formulation experiments	Synchronous per batch	Experimental conditions	Feeds both immediate and future delayed outputs into learning loop
Asynchronous update handler	Integrates delayed stability labels	Event-driven	Time-stamped outcomes	Updates model only when stability data matures, without interrupting optimization
Closed-loop controller	Coordinates learning and experiment selection	Continuous	Decision policy	Maintains optimization flow despite delayed outcome arrival

Multi-Objective Trade-Off and Pareto-Front Navigation

The platform would maintain an active Pareto archive in which candidate formulations are compared across critical quality attributes, including size, polydispersity, encapsulation, process robustness, and stability. Deep learning platforms for LNP development [9], AI-driven ionizable lipid design [10], AI-guided pulmonary gene therapy LNP design [11], and cellular-tropism modeling [25] all support the broader concept that formulation choices must be evaluated through multiple competing endpoints rather than a single response. Reviews of machine learning for LNP formulation emphasize that predictive models should be linked to practical formulation decisions, not merely retrospective prediction tasks [20–22]. In this framework, Pareto-front navigation would allow a scientist to select a candidate with a defensible risk-benefit profile, such as prioritizing long-term stability even when another candidate has a marginally stronger early delivery signal, consistent with self-driving laboratory principles for trade-off exploration.

Figure 3 shows how delayed stability measurements are integrated into Pareto-front navigation so that early LNP quality, storage robustness, process reliability, and human-supervised candidate selection are evaluated together.




Figure 3. Stability-Aware Pareto Navigation and Candidate Selection in Closed-Loop LNP Development

Closed-Loop Orchestration and Safety Guardrails

Software Architecture and Hardware Integration

The software layer would be organized around a central orchestrator that coordinates microfluidic pumps, process sensors, particle characterization modules, fluorescence-based assays, and stability tracking systems. Microfluidic RNA-LNP production studies demonstrate why such orchestration must account for chip design, flow configuration, and mixing behavior rather than treating fabrication as a black-box step [4, 15, 23]. Parallelized and throughput-scalable LNP manufacturing studies show how automated preparation can support repeated formulation cycles, while analytical characterization methods provide the measurement foundation needed for model updates [5, 6, 16]. The dashboard would display only authorized experiment states, quality trends, and Pareto-front summaries, ensuring that the platform remains an accountable decision-support system rather than an ungoverned autonomous generator.

Safety Limits and Failure Handling

The closed-loop system would include hard operating limits for pressure, flow, solvent compatibility, measurement validity, and sample routing, because LNP manufacturing outcomes are sensitive to both formulation composition and process conditions [4, 5, 23]. In addition to physical safety controls, the platform would include biosecurity guardrails appropriate for AI-assisted nucleic acid delivery research: nucleic acid synthesis screening, refusal of requests that seek harmful payload design or evasion of safeguards, misuse-pattern detection, end-to-end red teaming, institution-level access controls, and audit logs for all AI-generated formulation suggestions. These controls are justified by the increasing power of AI-guided LNP design platforms [9–11, 25], which could accelerate beneficial RNA medicines but also require governance when linked to automated delivery-system development. Out-of-spec batches, repeated measurement failures, or requests outside approved research boundaries would be quarantined or blocked, and human review would be required before any continuation of the experimental loop.

Deployment Pathways and Scalability

From R&D to Manufacturing

After a candidate formulation is selected, the same closed-loop architecture could support robustness studies around the selected design space rather than simply terminating at optimization. Scalable mRNA and siRNA LNP manufacturing work shows that automated microfluidic systems can be relevant beyond small exploratory screens [5, 6], while reviews of microfluidic RNA-LNP production emphasize the importance of translating controlled laboratory preparation into reproducible development workflows [4, 15]. Mixing-method and channel-design studies indicate that robustness testing should include process variability, device geometry, and mixing behavior as formulation-relevant factors [7, 24]. In a regulatory quality-by-design context, the platform would be expected to generate traceable formulation-process-quality relationships rather than unsupported claims of universal optimality.

Scaling to Multiple Payloads and Platforms

The platform should be designed as a modular AI core rather than a single-purpose workflow tied to one chip, one payload, or one lipid family. Lab-scale studies comparing siRNA and mRNA LNP manufacturing techniques [23] and co-delivery work involving siRNA and mRNA formulations [13] suggest that a flexible architecture could support multiple nucleic acid modalities while preserving payload-specific constraints. Phospholipid optimization [14], ionizable lipid design [10], pulmonary gene therapy applications [11], cellular-tropism modeling [12], and broader performance-prediction frameworks [22] all show that formulation knowledge can be reused but should not be transferred blindly. The platform would therefore build a cross-product knowledge base with payload-specific access controls, model versioning, and domain checks before applying learned relationships to new delivery contexts.

Evaluation Strategy

Table 3 provides a governance-centered evaluation framework for assessing whether the autonomous LNP formulation platform is efficient, scientifically reliable, stability-aware, misuse-resistant, and suitable for supervised deployment.

Table 3. Governance-Centered Evaluation Framework for Autonomous LNP Formulation Optimization

Evaluation domain	What should be evaluated	Recommended conceptual metric or assessment lens	Why it matters for closed-loop LNP optimization	Governance or safety implication
Optimization efficiency	Whether the AI platform reaches a useful Pareto region with fewer experimental cycles than static DoE	Learning progress per experimental cycle; convergence toward a stable Pareto archive	Demonstrates whether autonomy adds practical value beyond conventional screening	Prevents unnecessary experimental expansion and supports resource-conscious development
Surrogate-model reliability	Whether the Gaussian process model predicts CQAs and stability behavior with calibrated uncertainty	Hold-out prediction error, uncertainty calibration, prediction-interval coverage	Ensures that acquisition decisions are not based on overconfident or poorly calibrated predictions	Requires model monitoring before allowing autonomous continuation
Stability-aware decision quality	Whether selected candidates remain attractive after delayed stability readouts arrive	Agreement between early predicted stability and later observed stability descriptors	Prevents premature selection of formulations that appear strong only at initial characterization	Supports conservative decision-making when delayed risk signals emerge
Process robustness	Whether candidate formulations tolerate small changes in flow, pressure, mixing, and chip conditions	Local robustness testing around the selected design region	Distinguishes fragile optima from manufacturable formulation regions	Provides evidence for quality-by-design interpretation and scale-up planning
Measurement integrity	Whether assay drift or failed measurements distort model learning	Instrument-control trends, standard-sample checks, repeat-measurement consistency	Protects the surrogate model from learning artifacts caused by analytical noise	Triggers quarantine or human review when measurement validity is uncertain
Multi-objective transparency	Whether trade-offs among size, PDI, encapsulation, stability, and delivery-relevant attributes are visible to users	Pareto-front interpretability and documented candidate-selection rationale	Avoids opaque selection of a single formulation without explaining competing priorities	Supports accountable scientific review before formulation advancement
Biosecurity screening	Whether payload-related requests and nucleic acid inputs pass institutional safety controls	Screening status, request classification, access authorization, audit-log completeness	Ensures the platform is not used to assist harmful or unauthorized nucleic-acid delivery work	Blocks, refuses, or escalates unsafe requests before experimental execution
Misuse-resilience	Whether the platform resists attempts to bypass safety rules or generate inappropriate experimental plans	Red-team scenarios, policy-violation detection, refusal consistency	Tests the platform under adversarial or ambiguous use cases rather than only ideal workflows	Strengthens institutional trust and responsible deployment
Cross-platform transferability	Whether learned formulation knowledge can be reused across chips, payloads, or lipid families without overgeneralization	Domain-shift checks, model-version tracking, payload-specific validation requirements	Allows the knowledge base to accelerate future projects while respecting modality differences	Prevents unsafe extrapolation to unvalidated delivery contexts
Human oversight quality	Whether scientists can understand, approve, reject, or revise AI recommendations	Review documentation, override rationale, uncertainty display, approval workflow completeness	Maintains expert control over formulation decisions despite increasing automation	Ensures that final advancement remains human-supervised and auditable

Optimization Efficiency and Speed

Optimization efficiency would be evaluated by comparing how many conceptual formulation cycles are required to reach a satisfactory Pareto front under the AI-guided workflow versus a conventional design-of-experiments strategy. Bayesian optimization studies in pharmaceutical product development [8], vaccine formulation, biologics formulation, and broader biopharmaceutical formulation acceleration provide a rationale for measuring learning efficiency per experiment rather than relying only on final candidate quality. LNP-specific machine learning studies using XGBoost, Bayesian methods, ensemble models, and process-aware prediction show that model-guided formulation learning can be evaluated as an iterative decision process [2, 3, 19]. The evaluation would remain conceptual unless experimentally validated, avoiding unsupported numerical claims about batch counts, success rates, or performance improvements.

Predictive Accuracy of the Surrogate Model

Surrogate-model evaluation would assess whether predictions of size, polydispersity, encapsulation, and stability are both accurate and calibrated over successive closed-loop iterations. Machine learning approaches for mRNA vaccine LNP

prediction [2], deep learning-powered LNP development [9], AI-driven ionizable lipid design [10], and general nucleic acid delivery performance prediction [22] show why both descriptor quality and model uncertainty matter for reliable decision-making. Cellular-specific delivery modeling further highlights that prediction errors may vary across biological contexts, making calibration and uncertainty monitoring essential rather than optional [25]. Reviews of LNP machine learning emphasize that models should be assessed not only for retrospective fit but also for their usefulness in guiding formulation decisions [20, 21].

Quality and Stability of the Optimized Formulation

The final selected candidate would be evaluated against a conventionally developed comparator using the same predefined quality and stability criteria, while avoiding claims of superiority unless supported by actual experimental evidence. mRNA-LNP vaccine stability literature shows that structure, storage conditions, RNA integrity, and colloidal behavior must be interpreted together [1], and lyophilized mRNA-LNP studies demonstrate why stability-preserving formulation strategies remain central to product development [17, 18]. Analytical characterization methods would support comparison of particle attributes and formulation integrity [16], while mixing-method studies caution that apparent quality differences may reflect process history as well as composition [7]. The evaluation would also consider morphology and lipid chemistry, since ionizable lipid assembly [12] and phospholipid selection [14] can influence delivery-relevant behavior, including in AI-guided therapeutic delivery contexts [11].

Limitations

Sensitivity to Instrument Variability and Drift

A major limitation is that day-to-day variation in DLS, fluorescence assays, fluidic pressure readings, or temperature control could be misinterpreted by the Gaussian process as a true formulation effect. Lipid nanoparticle analytical characterization requires careful attention to measurement method, sample handling, and orthogonal confirmation [16]. Manufacturing-focused machine learning studies of LNP processes show that process variables must be captured consistently for reliable interpretation [2], while microfluidic evaluations indicate that device configuration and operating conditions can introduce variability that is not always visible in formulation metadata [4, 15, 23]. The platform would therefore require periodic standards, diagnostic checks, drift detection, and human review when measurement behavior deviates from expected ranges.

Incomplete Physicochemical Representation

A second limitation is that a platform trained mainly on critical quality attributes may miss molecular mechanisms that govern ionization, membrane disruption, intracellular trafficking, or tissue tropism. AI-driven ionizable lipid design shows the value of molecular-level representation [10], while foundational LNP morphology work and phospholipid-chemistry studies demonstrate that lipid structure and assembly influence delivery behavior in ways that simple CQA tables may not capture [12, 14]. Deep learning approaches for LNP development [9], pulmonary gene therapy formulation [11], cellular-tropism prediction [25], and nucleic-acid delivery performance modeling [22] suggest that richer descriptors could improve future systems. However, adding molecular descriptors, biological-response predictors, and payload-specific safety filters would also increase model complexity, validation burden, and governance requirements.

Conclusion

A closed-loop AI platform for lipid nanoparticle formulation would bring together automated microfluidic preparation, particle characterization, stability monitoring, Bayesian decision-making, and human-supervised governance. Its central contribution is not a claim of experimental superiority, but a framework for learning formulation-process-quality relationships in an adaptive and auditable way. By integrating biosecurity guardrails into the same architecture, the platform can be designed for responsible RNA nanomedicine development rather than unconstrained autonomous experimentation.

The strongest feature of the proposed system is its integration of microfluidic automation with uncertainty-aware Bayesian design. Instead of separating formulation screening, process optimization, and stability testing into disconnected phases, the platform treats them as linked data streams. Multi-objective Pareto navigation would allow formulation scientists to evaluate trade-offs transparently rather than relying on a single composite score.

Several challenges remain before such a system could be considered mature. Hardware robustness, assay drift, data interoperability, and incomplete mechanistic representation could all limit the reliability of autonomous decisions. Regulatory acceptance would also require clear documentation of model updates, constraint logic, safety interventions, and human oversight across the development lifecycle.

Future progress will depend on pre-competitive collaboration, shared reference datasets, transparent benchmarking, and open-source self-driving laboratory frameworks adapted specifically for nanomedicine. Responsible deployment should pair technical innovation with institutional access controls, payload screening, misuse monitoring, and independent red teaming. In this way, closed-loop AI formulation platforms could accelerate beneficial RNA therapeutics while preserving scientific accountability and biosafety.

Acknowledgments: None

Conflict of interest: None

Financial support: None

Ethics statement: None

References

1. Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *Int J Pharm*. 2021;601:120586.
2. Wang W, Feng S, Ye Z, Gao H, Lin J, Ouyang D. Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. *Acta Pharm Sin B*. 2022;12(6):2950-62.
3. Maharjan R, Kim KH, Lee K, Han HK, Jeong SH. Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches. *J Pharm Anal*. 2024;14(11):100996.
4. Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. *J Control Release*. 2022;344:80-96.
5. Shepherd SJ, Warzecha CC, Yadavali S, El-Mayta R, Alameh MG, Wang L, et al. Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device. *Nano Lett*. 2021;21(13):5671-80.
6. Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. *Proc Natl Acad Sci U S A*. 2023;120(33):e2303567120.
7. Petersen DM, Chaudhary N, Arral ML, Weiss RM, Whitehead KA. The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism. *Eur J Pharm Biopharm*. 2023;192:126-35.
8. Sano S, Kadowaki T, Tsuda K, Kimura S. Application of Bayesian optimization for pharmaceutical product development. *J Pharm Innov*. 2020;15(3):333-43.
9. Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. *Nat Commun*. 2024;15(1):6305.
10. Wang W, Chen K, Jiang T, Wu Y, Wu Z, Ying H, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. *Nat Commun*. 2024;15(1):10804.
11. Witten J, Raji I, Manan RS, Beyer E, Bartlett S, Tang Y, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. *Nat Biotechnol*. 2025;43(11):1790-9.
12. Kulkarni JA, Darjuan MM, Mercer JE, Chen S, Van Der Meel R, Thewalt JL, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. *ACS Nano*. 2018;12(5):4787-95.
13. Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. *Nano Lett*. 2018;18(6):3814-22.
14. Álvarez-Benedicto E, Farbiak L, Ramírez MM, Wang X, Johnson LT, Mian O, et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). *Biomater Sci*. 2022;10(2):549-59.
15. Lopes C, Cristóvão J, Silvério V, Lino PR, Fonte P. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. *Expert Opin Drug Deliv*. 2022;19(10):1381-95.
16. Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. *J Pharm Biomed Anal*. 2021;192:113642.
17. Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. *Cell Discov*. 2023;9(1):9.
18. Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. *Mol Ther*. 2022;30(5):1941-51.
19. Sato S, Sano S, Muto H, Kubara K, Kondo K, Miyazaki T, et al. Understanding the manufacturing process of lipid nanoparticles for mRNA delivery using machine learning. *Chem Pharm Bull*. 2024;72(6):529-39.
20. Dorsey PJ, Lau CL, Chang TC, Doerschuk PC, D'Addio SM. Review of machine learning for lipid nanoparticle formulation and process development. *J Pharm Sci*. 2024;113(12):3413-33.
21. Li H, Zhao Y, Xu C. Machine learning techniques for lipid nanoparticle formulation. *Nano Converg*. 2025;12(1):35.
22. Kumar G, Ardekani AM. Machine-learning framework to predict the performance of lipid nanoparticles for nucleic acid delivery. *ACS Appl Bio Mater*. 2025;8(5):3717-27.
23. Jürgens DC, Deßloch L, Porras-Gonzalez D, Winkeljann J, Zielinski S, Munschauer M, et al. Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques—an evaluation of particle properties and efficiency. *OpenNano*. 2023;12:100161.
24. Yu M, Liu D, Shah P, Qiu B, Mathew A, Yao L, et al. Optimizing microfluidic channel design with tilted rectangular baffles for enhanced mRNA-lipid nanoparticle preparation. *ACS Biomater Sci Eng*. 2025;11(6):3762-72.
25. Hanafy BI, Munson MJ, Soundararajan R, Pereira S, Gallud A, Sanaullah SM, et al. Advancing cellular-specific delivery: Machine learning insights into lipid nanoparticles design and cellular tropism. *Adv Healthc Mater*. 2025;14(18):2500383.